Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Pharmacology

Background:

• Neonatal chronic lung disease (CLD), or bronchopulmonary dysplasia, is a major complication in preterm infants.
• Postnatal corticosteroids are used to manage CLD, but safety and efficacy vary.
• Previous guidelines addressed corticosteroid use, necessitating an updated review.

Purpose of the Study:

• To review the evidence on postnatal corticosteroid use for CLD prevention and treatment in preterm infants.
• To evaluate the risks and benefits of different corticosteroids and administration timings.
• To provide updated recommendations for clinicians.

Main Methods:

• Systematic review of clinical trials and existing literature on postnatal corticosteroid therapy.
• Analysis of outcomes including CLD rates, mortality, and neurodevelopmental effects (e.g., cerebral palsy).
• Comparison of dexamethasone, hydrocortisone, and inhaled corticosteroids.

Main Results:

• Early postnatal corticosteroids (within 7 days) increase cerebral palsy risk and are not recommended for CLD prevention.
• Dexamethasone after 7 days of life can reduce CLD rates at 36 weeks' postmenstrual age with improved neurodevelopmental outcomes.
• Limited evidence supports hydrocortisone or routine inhaled corticosteroid use; inhaled corticosteroids may be an alternative for severe CLD treatment.

Conclusions:

• Routine early postnatal corticosteroid therapy for CLD prevention is contraindicated.
• Short-course, low-dose dexamethasone may be considered for high-risk infants with severe CLD after the first week of life.
• Further research is needed for optimal corticosteroid strategies in neonatal chronic lung disease.